Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Nkarta to $26 from $36 and keeps an Outperform rating on the shares after the company held an investor event to unveil updates from NKX019 in nonHodgkin’s lymphoma. The analyst thought "the data looked fine but were very incremental." The bigger problem right now, in his view, is how NKX019 differentiates itself from all the other CD19 therapies out there. The fact that there were only two new aggressive lymphoma patients since April suggests an increasingly competitive market, Biegler adds. If anything, he thinks the emerging safety profile portends favorably to AML, where he sees the biggest opportunity for NK cell therapy to shine.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NKTX:
- Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Nkarta announces updated clinical data on NKX019
- Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
- Nkarta price target lowered to $36 from $50 at Oppenheimer
- Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights